FDA Chooses 7 Companies for PreCheck Pilot

PharmTech.com· June 30, 2026

The U.S. Food and Drug Administration has announced the selection of seven companies to participate in its new PreCheck pilot program. This initiative aims to explore more efficient regulatory pathways and oversight mechanisms for the pharmaceutical industry. The program's outcomes could influence future compliance standards and the speed of regulatory approvals for participating manufacturers. By collaborating with these selected firms, the FDA intends to modernize its approach to industry oversight and supply chain integrity.

Read the full story at PharmTech.com

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to PharmTech.com.

More in Pharmaceutical

GAO Report Finds Federal Research Fuels Pharmaceutical Profits with Minimal Taxpayer Return

A new Government Accountability Office (GAO) report released in June 2026 investigates how federal research funding translates into private pharmaceutical profits. The report highlights the role of agencies like the National Institutes of Health (NIH) in bearing the financial risk of early-stage discovery before private companies license the findings for commercial development. This examination is critical for the pharmaceutical sector as it addresses the growing tension between public investment in innovation and the high cost of resulting medications for U.S. patients.

June 30, 2026

Seven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chain

The U.S. Food and Drug Administration has selected seven companies to participate in a new pilot program focused on strengthening the domestic pharmaceutical supply chain. This initiative aims to enhance the security and resilience of drug distribution networks to prevent critical medicine shortages. For the pharmaceutical sector, this program represents a significant effort to modernize logistics and ensure the continuous availability of essential treatments for patients. By collaborating with industry partners, the FDA seeks to identify best practices that can be scaled to protect the integrity of the entire U.S. drug market.

June 30, 2026

Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme

Eli Lilly and Regeneron have been identified as early participants in the FDA’s new fast-track facility scheme. This program is designed to expedite the regulatory review and approval process for pharmaceutical manufacturing sites. By streamlining these inspections, the initiative aims to facilitate faster market entry for critical medications and improve supply chain efficiency. The involvement of these major incumbents underscores the pharmaceutical industry's move toward modernized regulatory frameworks for production infrastructure.

June 30, 2026

Treating Duchenne muscular dystrophy before symptoms emerge may improve motor function, clinical trial suggests

Researchers at Binghamton University have published Phase II clinical trial data suggesting that early intervention with vamorolone (Agamree) significantly improves motor function in young children with Duchenne muscular dystrophy (DMD). The study focused on steroid-naive boys aged two to four, a younger demographic than typically treated with standard corticosteroids, which often carry severe side effects like growth stunting. These findings are particularly significant for the pharmaceutical sector as DMD was recently added to the U.S. Recommended Universal Screening Panel, potentially opening a market for newborn and presymptomatic treatments.

June 30, 2026